Cognitive Neurology Clinical Trials
NYU Langone’s Center for Cognitive Neurology conducts clinical trials to identify new and promising approaches to treatment for neurological diseases that affect cognition.
To find out whether you are eligible to participate in a clinical trial, please call 212-263-3257 or email email@example.com.
Studies for People with Mild Cognitive Impairment and/or Alzheimer’s Disease
Current clinical trials being conducted at the Center for Cognitive Neurology include the following.
Phase 2 Study of BIIB092 in Participants with Early Alzheimer’s Disease (TANGO)
The TANGO Study is evaluating the safety, dosing, and potential effectiveness of a new investigational drug to see whether it has the potential to be a helpful treatment that slows down disease progression in people with mild cognitive impairment due to Alzheimer’s disease or with mild Alzheimer’s disease. The investigational drug is designed to target the tau protein, which is one of the key proteins that build up in the brains of people who have Alzheimer’s disease. Researchers believe the investigational drug may help reduce the spread of tau in the brain, potentially slowing the progress of the disease. You may join this study if you are 50 to 80 years of age, have mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease, have a caregiver who can accompany you to clinic visits, and are in general good health. For more information, email firstname.lastname@example.org. See full clinical trial information.
Antiviral Therapy in Alzheimer’s Disease
This study is investigating the efficacy of treating people who have Alzheimer’s disease with the generic antiviral drug valacyclovir. Valacyclovir taken at 2 to 4 g daily, repurposed as an anti–Alzheimer’s disease drug, is being compared with matching placebo in the treatment of 130 people who have mild Alzheimer’s disease (65 valacyclovir, 65 placebo) and who test positive for herpes simplex virus-1 (HSV1) or herpes simplex virus-2 (HSV2). The study is a randomized, double-blind, 18-month phase II proof of concept trial. This study is funded by the NIH. For information, email email@example.com. See full clinical trial information.
SUVN-502 with Donepezil and Memantine for the Treatment of Moderate Alzheimer’s Disease
This is a phase II research trial of an oral investigational medication called SUVN-502. We are testing SUVN-502’s effectiveness on the symptoms of moderate Alzheimer’s disease when given alongside standard treatments of donepezil (Aricept®) and memantine (Namenda®). The trial is for individuals between the ages of 50 and 85 who have been diagnosed with Alzheimer’s disease for at least a year. Participation consists of 26 weeks of double-blind (possibility of placebo) treatment. An accompanying caregiver is mandatory. Please note that participants cannot be taking any other Alzheimer’s disease medication during the course of the trial except donepezil and memantine.
Exercise in Adults with Mild Memory Problems (EXERT)
EXERT is an 18-month-long national clinical trial testing whether physical exercise can slow the progression of memory problems or mild cognitive impairment related to early Alzheimer’s disease in older adults. Participants must be able to exercise at a participating local YMCA 4 times per week for 18 months. Participants must also be able to come to the clinic for physical exams, blood collection, cognitive testing, and brain imaging. Eligible adults must be willing to participate in either of the two exercise treatment assignment groups.
We are currently enrolling adults between the ages of 65 and 89 who are experiencing mild memory loss or lapses and/or who have been diagnosed with mild cognitive impairment, have not been regularly exercising, and are otherwise in good health.
Memory Improvement Through Nicotine Dosing (MIND) Study
The MIND study seeks to determine whether daily transdermal nicotine has a positive effect on early memory loss in people diagnosed with mild cognitive impairment. We are enrolling healthy, nonsmoking adults over the age of 55. There is no cost to participate.
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3) Protocol
This is a nonrandomized, natural history nontreatment study. Participants need to be between 55 and 90 years, and be healthy with no neurologic disease such as Alzheimer’s disease. Subjects undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid, and tau) and MRI scans, and cerebral spinal fluid (CSF) collection for up to five years.
Studies for the Prevention of Cognitive Impairment
A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer’s Disease Using F18 Flutemetamol
The purpose of this study is to determine whether the use of selected antidepressant medications in persons with subjective memory complaints is a useful strategy in preventing progression to mild cognitive impairment (isolated memory loss) or dementia (Alzheimer’s disease).
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (Generation S1)
The Generation Study 1 study will assess whether CAD106 and/or CNP520 (given separately) are safe and have beneficial effects in people who may be at elevated risk for the onset of clinical symptoms of Alzheimer’s disease because of their age and genetic status (carrying two copies of a gene called APOE4). The study will also observe and measure the biological response to the study drugs in the body, and it will evaluate the safety and tolerability of CAD106 and CNP520.
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (Generation S2)
The Generation Study 2 will evaluate the safety and effectiveness of an experimental drug called CNP520 to see whether it is safe in people who are at higher risk for having symptoms of Alzheimer’s disease and whether it has an effect on the progression of the disease. The study will look for effects of CNP520 on memory and other thinking abilities, mood, everyday activities, and changes in the brain. The CNP520 will be tested for its ability to delay the buildup of amyloid β into amyloid plaques, which are associated with Alzheimer’s disease.